242 related articles for article (PubMed ID: 36482272)
1. An update on the pathological classification of breast cancer.
Rakha EA; Tse GM; Quinn CM
Histopathology; 2023 Jan; 82(1):5-16. PubMed ID: 36482272
[TBL] [Abstract][Full Text] [Related]
2. New Advances in Molecular Breast Cancer Pathology.
Rakha EA; Pareja FG
Semin Cancer Biol; 2021 Jul; 72():102-113. PubMed ID: 32259641
[TBL] [Abstract][Full Text] [Related]
3. Specific cell differentiation in breast cancer: a basis for histological classification.
Rakha E; Toss M; Quinn C
J Clin Pathol; 2022 Feb; 75(2):76-84. PubMed ID: 34321225
[TBL] [Abstract][Full Text] [Related]
4. Molecular classification of breast cancer: what the pathologist needs to know.
Rakha EA; Green AR
Pathology; 2017 Feb; 49(2):111-119. PubMed ID: 28040199
[TBL] [Abstract][Full Text] [Related]
5. The molecular basis of breast cancer pathological phenotypes.
Heng YJ; Lester SC; Tse GM; Factor RE; Allison KH; Collins LC; Chen YY; Jensen KC; Johnson NB; Jeong JC; Punjabi R; Shin SJ; Singh K; Krings G; Eberhard DA; Tan PH; Korski K; Waldman FM; Gutman DA; Sanders M; Reis-Filho JS; Flanagan SR; Gendoo DM; Chen GM; Haibe-Kains B; Ciriello G; Hoadley KA; Perou CM; Beck AH
J Pathol; 2017 Feb; 241(3):375-391. PubMed ID: 27861902
[TBL] [Abstract][Full Text] [Related]
6. Advanced Approaches to Breast Cancer Classification and Diagnosis.
Zubair M; Wang S; Ali N
Front Pharmacol; 2020; 11():632079. PubMed ID: 33716731
[TBL] [Abstract][Full Text] [Related]
7. A new gene expression signature, the ClinicoMolecular Triad Classification, may improve prediction and prognostication of breast cancer at the time of diagnosis.
Wang DY; Done SJ; McCready DR; Boerner S; Kulkarni S; Leong WL
Breast Cancer Res; 2011 Sep; 13(5):R92. PubMed ID: 21939527
[TBL] [Abstract][Full Text] [Related]
8. Breast cancer intratumour heterogeneity: current status and clinical implications.
Joseph C; Papadaki A; Althobiti M; Alsaleem M; Aleskandarany MA; Rakha EA
Histopathology; 2018 Nov; 73(5):717-731. PubMed ID: 29722058
[TBL] [Abstract][Full Text] [Related]
9. Myxovirus resistance 1 (MX1) is an independent predictor of poor outcome in invasive breast cancer.
Aljohani AI; Joseph C; Kurozumi S; Mohammed OJ; Miligy IM; Green AR; Rakha EA
Breast Cancer Res Treat; 2020 Jun; 181(3):541-551. PubMed ID: 32350677
[TBL] [Abstract][Full Text] [Related]
10. Head to head: do neuroendocrine tumours in the breast truly exist?
Rakha E; Tan PH
Histopathology; 2022 Jul; 81(1):2-14. PubMed ID: 35133666
[TBL] [Abstract][Full Text] [Related]
11. Overview of resistance to systemic therapy in patients with breast cancer.
Gonzalez-Angulo AM; Morales-Vasquez F; Hortobagyi GN
Adv Exp Med Biol; 2007; 608():1-22. PubMed ID: 17993229
[TBL] [Abstract][Full Text] [Related]
12. Tumour Heterogeneity of Breast Cancer: From Morphology to Personalised Medicine.
Aleskandarany MA; Vandenberghe ME; Marchiò C; Ellis IO; Sapino A; Rakha EA
Pathobiology; 2018; 85(1-2):23-34. PubMed ID: 29428954
[TBL] [Abstract][Full Text] [Related]
13. Breast cancer prognostic classification in the molecular era: the role of histological grade.
Rakha EA; Reis-Filho JS; Baehner F; Dabbs DJ; Decker T; Eusebi V; Fox SB; Ichihara S; Jacquemier J; Lakhani SR; Palacios J; Richardson AL; Schnitt SJ; Schmitt FC; Tan PH; Tse GM; Badve S; Ellis IO
Breast Cancer Res; 2010; 12(4):207. PubMed ID: 20804570
[TBL] [Abstract][Full Text] [Related]
14. Triple-negative/basal-like breast cancer: review.
Rakha EA; Ellis IO
Pathology; 2009 Jan; 41(1):40-7. PubMed ID: 19089739
[TBL] [Abstract][Full Text] [Related]
15. Breast cancer molecular subtypes in oman: correlation with age, histology, and stage distribution - analysis of 542 cases.
Mehdi I; Monem AA; Al Bahrani B; Ramadhan FA
Gulf J Oncolog; 2014 Jan; 1(15):38-48. PubMed ID: 24610287
[TBL] [Abstract][Full Text] [Related]
16. Schlafen-11 expression is associated with immune signatures and basal-like phenotype in breast cancer.
Isnaldi E; Ferraioli D; Ferrando L; Brohée S; Ferrando F; Fregatti P; Bedognetti D; Ballestrero A; Zoppoli G
Breast Cancer Res Treat; 2019 Sep; 177(2):335-343. PubMed ID: 31222709
[TBL] [Abstract][Full Text] [Related]
17. Modern classification of breast cancer: should we stick with morphology or convert to molecular profile characteristics.
Rakha EA; Ellis IO
Adv Anat Pathol; 2011 Jul; 18(4):255-67. PubMed ID: 21654357
[TBL] [Abstract][Full Text] [Related]
18. The quantitative detection of total HER2 load by quantum dots and the identification of a new subtype of breast cancer with different 5-year prognosis.
Chen C; Xia HS; Gong YP; Peng J; Peng CW; Hu MB; Zhu XB; Pang DW; Sun SR; Li Y
Biomaterials; 2010 Nov; 31(33):8818-25. PubMed ID: 20723971
[TBL] [Abstract][Full Text] [Related]
19. Molecular biology of breast cancer.
Martín M
Clin Transl Oncol; 2006 Jan; 8(1):7-14. PubMed ID: 16632434
[TBL] [Abstract][Full Text] [Related]
20. RERG (Ras-like, oestrogen-regulated, growth-inhibitor) expression in breast cancer: a marker of ER-positive luminal-like subtype.
Habashy HO; Powe DG; Glaab E; Ball G; Spiteri I; Krasnogor N; Garibaldi JM; Rakha EA; Green AR; Caldas C; Ellis IO
Breast Cancer Res Treat; 2011 Jul; 128(2):315-26. PubMed ID: 20697807
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
